| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to … PD Kottaridis, RE Gale, ME Frew, G Harrison, SE Langabeer, AA Belton, ... Blood, The Journal of the American Society of Hematology 98 (6), 1752-1759, 2001 | 1998 | 2001 |
| In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation PD Kottaridis, DW Milligan, R Chopra, RK Chakraverty, S Chakrabarti, ... Blood, The Journal of the American Society of Hematology 96 (7), 2419-2425, 2000 | 609 | 2000 |
| High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution S Chakrabarti, S Mackinnon, R Chopra, PD Kottaridis, K Peggs, ... Blood, The Journal of the American Society of Hematology 99 (12), 4357-4363, 2002 | 433 | 2002 |
| Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen R Chakraverty, K Peggs, R Chopra, DW Milligan, PD Kottaridis, ... Blood, The Journal of the American Society of Hematology 99 (3), 1071-1078, 2002 | 403 | 2002 |
| Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in … PD Kottaridis, RE Gale, SE Langabeer, ME Frew, DT Bowen, DC Linch Blood, The Journal of the American Society of Hematology 100 (7), 2393-2398, 2002 | 388 | 2002 |
| RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years DT Bowen, ME Frew, R Hills, RE Gale, K Wheatley, MJ Groves, ... Blood 106 (6), 2113-2119, 2005 | 331 | 2005 |
| No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute … RE Gale, R Hills, PD Kottaridis, S Srirangan, K Wheatley, AK Burnett, ... Blood 106 (10), 3658-3665, 2005 | 286 | 2005 |
| Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders JA Pérez-Simón, PD Kottaridis, R Martino, C Craddock, D Caballero, ... Blood, The Journal of the American Society of Hematology 100 (9), 3121-3127, 2002 | 267 | 2002 |
| The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation A Knight, AJ Madrigal, S Grace, J Sivakumaran, P Kottaridis, S Mackinnon, ... Blood, The Journal of the American Society of Hematology 116 (12), 2164-2172, 2010 | 234 | 2010 |
| Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia RE Gale, R Hills, AR Pizzey, PD Kottaridis, D Swirsky, AF Gilkes, ... Blood 106 (12), 3768-3776, 2005 | 233 | 2005 |
| Flt3 mutations and leukaemia. P D Kottaridis, RE Gale, DC Linch British journal of haematology 122 (4), 2003 | 221 | 2003 |
| Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data RF Duarte, BE Shaw, P Marin, P Kottaridis, M Ortiz, C Morante, J Delgado, ... Bone Marrow Transplantation 46 (1), 52-58, 2011 | 164 | 2011 |
| Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies K Branson, R Chopra, PD Kottaridis, G McQuaker, A Parker, S Schey, ... Journal of clinical oncology 20 (19), 4022-4031, 2002 | 140 | 2002 |
| Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell–depleted allogeneic transplantation for Hodgkin … KS Peggs, I Kayani, N Edwards, P Kottaridis, AH Goldstone, DC Linch, ... Journal of Clinical Oncology 29 (8), 971-978, 2011 | 129 | 2011 |
| Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution R Chakraverty, G Orti, M Roughton, J Shen, A Fielding, P Kottaridis, ... Blood, The Journal of the American Society of Hematology 116 (16), 3080-3088, 2010 | 115 | 2010 |
| Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist? EP Nacheva, CD Grace, D Brazma, K Gancheva, J Howard‐Reeves, ... British journal of haematology 161 (4), 541-550, 2013 | 112 | 2013 |
| The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro AJ Steele, DT Jones, K Ganeshaguru, VM Duke, BC Yogashangary, ... Leukemia 20 (6), 1073-1079, 2006 | 99 | 2006 |
| The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia A Giannoudis, L Wang, AL Jorgensen, G Xinarianos, A Davies, ... Blood, The Journal of the American Society of Hematology 121 (4), 628-637, 2013 | 95 | 2013 |
| Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality S Chakrabarti, I Avivi, S Mackinnon, K Ward, PD Kottaridis, H Osman, ... British journal of haematology 119 (4), 1125-1132, 2002 | 94 | 2002 |
| p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism AJ Steele, AG Prentice, AV Hoffbrand, BC Yogashangary, SM Hart, ... Blood, The Journal of the American Society of Hematology 112 (9), 3827-3834, 2008 | 92 | 2008 |
